featured
2020 Top Stories in Bladder Cancer: Nadofaragene Firadenovec Emerges as a New Treatment Option for BCG-Unresponsive Disease
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2020 Nov 27. doi: 10.1016/S1470-2045(20)30540-4. Online ahead of print.
- Steinberg RL, Thomas LJ, O’Donnell MA, Nepple KG. Sequential intravesical gemcitabine and docetaxel as salvage therapy for nonmuscle invasive bladder cancer. Bladder Cancer. 2015;1(1):65-72.
- Kamat AM, Sylvester RJ, Bohle A, et al. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016;34(16):1935-1944.